Bionano Genomics, Inc. (BNGO)
NASDAQ: BNGO · Real-Time Price · USD
1.200
-0.040 (-3.23%)
At close: Sep 4, 2026, 4:00 PM EDT
1.210
+0.010 (0.83%)
After-hours: Sep 4, 2026, 7:37 PM EDT
Bionano Genomics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 30.18 | 28.51 | 30.78 | 36.12 | 27.8 | 17.98 |
| 30.18 | 28.51 | 30.78 | 36.12 | 27.8 | 17.98 | |
Revenue Growth | 10.03% | -7.37% | -14.79% | 29.90% | 54.62% | 111.47% |
Cost of Revenue | 15.84 | 15.32 | 30.4 | 26.55 | 21.86 | 14.11 |
Gross Profit | 14.34 | 13.19 | 0.38 | 9.57 | 5.95 | 3.87 |
Selling, General & Admin | 34.33 | 35.15 | 62.75 | 94.22 | 86.48 | 56.92 |
Research & Development | 12.2 | 11.37 | 24.8 | 54.03 | 49.05 | 22.49 |
Operating Expenses | 46.53 | 46.52 | 87.55 | 148.25 | 135.53 | 79.41 |
Operating Income | -32.19 | -33.34 | -87.17 | -138.69 | -129.58 | -75.54 |
Interest Expense | -0.28 | -0.3 | -2.04 | -5.12 | -0.3 | -0.93 |
Interest & Investment Income | 0.91 | 1.11 | 2.1 | 3.31 | 1.51 | 0.24 |
Other Non Operating Income (Expenses) | -0.54 | 6.2 | -4.69 | -15.38 | -0.12 | -0.06 |
EBT Excluding Unusual Items | -32.1 | -26.33 | -91.79 | -155.87 | -128.5 | -76.29 |
Merger & Restructuring Charges | - | - | -8.02 | -0.74 | -1.8 | -1.5 |
Impairment of Goodwill | - | - | - | -77.28 | - | - |
Gain (Loss) on Sale of Investments | - | - | - | - | -0.1 | - |
Asset Writedown | - | - | -19.68 | - | - | - |
Other Unusual Items | - | - | 7.51 | 1.46 | -0.32 | -0.37 |
Pretax Income | -32.1 | -26.33 | -111.98 | -232.43 | -130.71 | -78.15 |
Income Tax Expense | 0.07 | 0.07 | 0.03 | 0.06 | 1.88 | -5.72 |
Net Income | -32.16 | -26.4 | -112.02 | -232.49 | -132.6 | -72.44 |
Net Income to Common | -32.16 | -26.4 | -112.02 | -232.49 | -132.6 | -72.44 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 10 | 5 | 1 | 1 | 0 | 0 |
Shares Outstanding (Diluted) | 10 | 5 | 1 | 1 | 0 | 0 |
Shares Change | 314.06% | 328.40% | 123.37% | 18.05% | 4.49% | 165.50% |
EPS (Basic) | -3.37 | -4.85 | -88.13 | -408.60 | -275.09 | -157.02 |
EPS (Diluted) | -3.37 | -4.85 | -88.13 | -408.60 | -275.09 | -157.02 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -20.48 | -16.35 | -69.03 | -126.87 | -128.02 | -73.39 |
Free Cash Flow Per Share | -2.15 | -3.00 | -54.31 | -222.97 | -265.58 | -159.09 |
Gross Margin | 47.50% | 46.25% | 1.23% | 26.49% | 21.38% | 21.55% |
Operating Margin | -106.68% | -116.95% | -283.23% | -384.00% | -466.09% | -420.08% |
Profit Margin | -106.58% | -92.59% | -363.97% | -643.74% | -476.93% | -402.84% |
Free Cash Flow Margin | -67.87% | -57.34% | -224.28% | -351.29% | -460.46% | -408.14% |
EBITDA | -22.87 | -23.81 | -73.15 | -124.98 | -119.96 | -72.18 |
EBITDA Margin | -75.80% | -83.53% | -237.67% | - | - | - |
D&A For EBITDA | 9.32 | 9.53 | 14.02 | 13.71 | 9.62 | 3.35 |
EBIT | -32.19 | -33.34 | -87.17 | -138.69 | -129.58 | -75.54 |
EBIT Margin | -106.68% | -116.95% | -283.23% | - | - | - |
Revenue as Reported | 30.18 | 28.51 | 30.78 | 36.12 | 27.8 | 17.98 |